# A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

> **NCT01974440** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 403 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** PCI-32765 (Ibrutinib)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01974440
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-31
- **Primary completion:** 2022-05-30
- **Final completion:** 2023-06-21
- **Target enrollment:** 403 (ACTUAL)
- **Last updated:** 2025-05-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01974440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01974440, "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01974440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*